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Abstract
Background: Malignant tumors arising from the vulva account for only 0.6 % of all cancers in female patients. The
predominant histologic type, representing about 90 % of these malignancies, is squamous cell carcinoma. Eccrine
porocarcinoma is a rare malignant tumor arising from sweat glands. The incidence of eccrine porocarcinoma is estimated
at 0.005–0.01 % of all cutaneous tumors. To the best of our knowledge, only seven previous cases of vulvar eccrine
porocarcinoma have been reported in the English-language literature. We present the case of a patient with eccrine
porocarcinoma of the vulva, and we summarize the clinical features of this disease using seven previously reported cases.
Case presentation: A 54-year-old Japanese woman visited a local hospital complaining of fever and left vulvar
pain for 2 months. An initial examination revealed a 1 × 1 cm, firm, ulcerative mass in the inner aspect of the
left labium minorum. With a preoperative diagnosis of vulvar squamous cell carcinoma, we performed a
radical local excision followed by bilateral inguinal lymphadenectomy. Histological examination showed eccrine
porocarcinoma, stage IB (T1bN0M0). Radiation therapy with weekly cisplatin administration was then given as adjuvant
therapy. One month after treatment was completed, computed tomography revealed multiple metastases in the
bilateral lungs and in the sacral bone. The patient received three courses of chemotherapy (paclitaxel and carboplatin)
and underwent palliative radiation therapy to the sacrum. She died of her disease 12 months after surgery.
Conclusions: We report the case of a patient with eccrine porocarcinoma of the vulva and summarize the clinical
features and the treatment options of eccrine porocarcinoma from a few retrospective case reports. Although eccrine
porocarcinoma is a rare disease, clinicians and pathologists should be aware of its clinical and histological features and
its biological behavior.
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Background
Malignant tumors arising from the vulva account for
5 % of reproductive organ cancers and 0.6 % of all can-
cers in female patients [1]. The predominant histologic
type is squamous cell carcinoma (SCC), representing
about 90 % of all cases. Less common histologic types
include melanoma (5–10 % of malignant vulvar cancers)
and basal cell carcinoma (approximately 2 %). Eccrine
porocarcinoma (EPC) is a very rare malignant tumor; it
arises from sweat glands and accounts for an estimated
0.005–0.01 % of all cutaneous tumors [2, 3]. There are
two pathways of EPC tumorigenesis: de novo generation
and transformation from a benign precursor lesion such
as a poroma. EPC should be considered in the differen-
tial diagnosis of skin cancer when the tumor is unusually
deep and there is no obvious epidermal involvement. To
the best of our knowledge, only seven other cases of
vulvar eccrine porocarcinoma have been reported in the
English-language literature [4–9]. Here, we report a pa-
tient with EPC of the vulva. We summarize the clinical
features of the disease, using our patient and seven pre-
viously reported patients.
Case presentation
A 54-year-old gravida 2 para 2 Japanese woman vis-
ited her local hospital, complaining of fever and left
vulvar pain over a 2-month period. She had a past
medical history of appendicitis at 13 years of age,
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erythema nodosum at 20 years of age, and hyperten-
sion diagnosed at 50 years of age. Her menopause oc-
curred at 53 years of age. The initial examination
revealed a 10 × 6 mm, firm, ulcerative mass on the
inner side of the left labium minorum (Fig. 1a). A
vulvar abscess was suspected at the initial visit, but
treatment with antibiotics was not effective. SCC was
strongly suspected by a subsequent needle biopsy, and
she was referred to our hospital for further treatment.
Upon admission, her physical examination revealed an
ulcerative mass on the left side of the vulva that had
increased in size to 31 × 24 mm. Our patient under-
went a diagnostic workup that included magnetic res-
onance imaging, revealing that the primary lesion did
not involve the urethra or anus (Fig. 1b). Neither
inguinal lymphadenopathy nor distant metastases
were seen on computed tomography (CT). With a
preoperative diagnosis of vulvar SCC, our patient
underwent radical local excision and bilateral inguinal
lymphadenectomy. Histopathological examination found
eccrine porocarcinoma with a depth of invasion of more
than 20 mm; marked vascular invasion was present. The
inguinal lymph nodes were negative for metastatic disease,
and the surgical margins of the resected lesion were also
negative. Our patient was diagnosed with stage IB disease
(T1bN0M0; International Federation of Gynecology and
Obstetrics 2008). To prevent local recurrence, she
underwent adjuvant radiation therapy for the pelvis,
bilateral inguinal area, and vulva (50.4 Gy/28 Fr) with
concurrent administration of weekly cisplatin (40 mg/
m2) for five cycles. One month after her treatment
was completed, positron emission tomography CT re-
vealed metastases to the sacrum (Fig. 1c) and multiple
small nodes in both lungs. She received three further
courses of chemotherapy (paclitaxel and carboplatin)
and underwent palliative radiation therapy to the
sacrum. At 12 months after surgery, our patient died
of her disease.
Fig. 1 Physical examination and clinical imaging. a Ulcerative lesion on the inner side of the left labium minorum (arrow). b T1-weighted,
contrast-enhanced magnetic resonance image revealing a 31 × 24 mm mass of moderate-to-high intensity in the left vulvar region (arrow); the
mass does not involve the urethra or anus. c Positron emission tomography computed tomography revealing tumor metastases to the sacrum (arrow)
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Histopathologic findings
Histological examination revealed polygonal tumor cells
with variable nuclear atypia and increased mitotic activ-
ity. The tumor lesions were broadly connected to the
epidermis, but the presence of a direct connection to the
squamous epithelium was unclear (Fig. 2a). The tumor
cells appeared as solid nests resembling large alveolar
glands, without apparent keratinization (Fig. 2b). In
addition to the intracytoplasmic luminal and cribriform
pattern, necrosis was seen in the center of the nodules,
giving the appearance of comedo-necrosis (Fig. 2b).
Based on these findings on hematoxylin and eosin-
stained sections, the differential diagnosis included SCC,
adenosquamous cell carcinoma, adenocarcinoma, sweat
gland carcinoma, and mammary-type ductal adenocar-
cinoma. Additional immunohistochemical examinations
were performed (Table 1). The tumor was strongly posi-
tive for CAM5.2, partially positive for 34βE12, focally
positive for carcinoembryonic antigen (CEA) (Fig. 2c),
and negative for cancer antigen 125 expression. The
tumor was strongly positive for p16 expression, and al-
most negative for the squamous cell markers p63 and
p40. The neuroendocrine markers chromogranin A and
synaptophysin were partially positive. The tumor was
negative for the apocrine marker BRST-2 (also known as
gross cystic disease fluid protein-15); estrogen, proges-
terone, and androgen receptors; human epidermal
growth factor receptor 2 (HER2); p53; and mucin 1,
cell surface associated (MUC-1) expression. Epithelial-
membrane antigen (EMA) expression was positive at
the luminal rims (Fig. 2d). The tumor was focally
positive for S-100 and positive for Ber-EP4 expres-
sion. These findings were consistent with the diagno-
sis of vulvar porocarcinoma.
Discussion
Primary adenocarcinoma arising from the eccrine sweat
glands is very rare, representing approximately 0.005 %
of epithelial cutaneous neoplasms [3]; EPC is the most
common variant of this type of malignancy. Macroscop-
ically, EPC can appear as a nodule, a polypoid ulcerating
lesion, or a plaque with an infiltrative or erosive pattern.
The lower extremities and the head and neck are the
most frequent sites of EPC origin [10, 11]. It is very rare
for the lesion to arise in the vulva: only seven cases of
invasive vulvar EPC have been reported in the English-
language literature (Table 2). The mean age at diagnosis
in these seven patients was 61 years (range, 32–80
years). Four patients had a favorable outcome with surgi-
cal treatment alone, but the other four, including our
patient, had recurrent or metastatic disease in spite of
multidisciplinary treatment.
Local and regional recurrence rates of EPC are report-
edly approximately 20 % [11]. The distant metastasis rate
Fig. 2 Histopathology and immunohistochemistry of sections of vulva tumor. a Tumor cells appearing as solid nests of cells resembling large
alveolar glands, broadly connected to the epidermis (arrow) (hematoxylin and eosin [H&E] staining; magnification × 40). b Tumor cells forming
small glandular structures (arrowheads); areas of comedo-necrosis are seen (arrows) (H&E; magnification × 100). c Tumor cells immunopositive for
carcinoembryonic antigen at the lumen (arrows) (magnification × 400. d Tumor cells immunopositive for epithelial membrane antigen at the
lumenal rims (arrows) (magnification × 400)
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is reportedly 12 %, and, more importantly, the mortal-
ity rate of metastatic EPC ranges from 75 to 80 %
[10]. EPC usually has a poor prognosis, regardless of
aggressive therapy, especially when it affects younger
patients [3, 7]. The following histological factors are
associated with aggressive behavior in EPC: tumor
depth greater than 7 mm, lymphovascular invasion,
and greater than 14 mitotic figures per 10 high-power
fields [10]. Our patient’s tumor met all three criteria.
EPC has been classified into three subtypes: infiltra-
tive, pushing, and pagetoid, based on the infiltrative
pattern at the margins [10, 12]. The infiltrative and
pagetoid patterns are predictive of local recurrence [10].
Belin et al. reported that four of ten patients with infiltra-
tive and two of two with pagetoid EPC developed recur-
rence, whereas none of the seven patients with a pushing
pattern experienced recurrence. Based on these findings,
they propose a surgical decisional algorithm based on the
EPC histological subtype [12].
A histopathological misdiagnosis of EPC might result
in inappropriate treatment and an unfavorable outcome.
Unfortunately, the precise diagnosis of EPC lesions can
be difficult because of their rareness and diverse histo-
logical features that are somewhat similar to those of
other skin neoplasms. EPC has heterogenous histology
that includes squamous cells, mucinous cells, clear cells,
pigmented cells, and spindle cells [9]. Morphologically
varied tumor cells may contribute to the relatively high
rates of misdiagnosis, particularly from small biopsy
specimens. A report by Belin et al. described 37 % of pa-
tients with skin EPC receiving the wrong diagnosis based
on initial histological evaluation [12]. In the same report,
five of 24 EPC lesions were misdiagnosed as SCC [12],
indicating that the initial misdiagnosis of the biopsy in
our patient was not unusual.
Most patients with EPC are treated with a surgical
procedure that includes wide local excision and evalu-
ation of margins by frozen section. The routine dissec-
tion of regional lymph nodes remains controversial,
although lymphadenectomy is indicated for patients with
clinically enlarged nodes. Radiation therapy for EPC is
ineffective for the control of recurrence or meta-
static disease [3, 5]. In addition, metastatic EPC has
proven resistant to many cytotoxic agents [13]. Com-
bination chemotherapy regimens obtain only short
remission times and frequently have severe adverse
effects [14]. Therefore, chemotherapy has only been
used sporadically. Currently, no effective treatment
for advanced or relapsed EPC has been found; more
information is needed.
Table 1 Summary of immunohistochemical examinations
Antibody CAM5.2 34βE12 CEA CA125 p16 p63 p40 Chromogranin A Synaptophysin BRST-2
Staining ++ + + - ++ - - + + -
Antibody ER PR AR HER2 p53 MUC-1 EMA S-100 Ber-EP4
Staining - - - - - - + + +
Abbreviations: CAM5.2 Cytokeratin CAM5.2, 34βE12 Cytokeratin 34βE12, CEA carcinoembryonic antigen, CA125 cancer antigen 125, ER estrogen receptor, PR
progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2, MUC-1 mucin 1, cell surface associated, EMA epithelial membrane
antigen, S-100 S-100 protein
Table 2 Summary of eight reported cases with eccrine porocarcinoma of the vulva
Age (years) Location, (size:cm) Initial treatment Additional treatment Outcome Author




Death due to unrelated
disease
Wick, 1985 [4]
75 Labium majus, (2 × 3) Radical hemivulvectomy and
lymph node dissection,
postoperative radiation
None No evidence of disease Katsanis, 1996 [5]
88 Labium majus, (3 × 2) Local excision None No evidence of disease Stephen,1998 [6]
32 Mons pubis, labium
majus, (4.5)
Chemotherapy and radiation None Early extensive
metastasis
Liegl, 2005 [7]
60 Labium majus, (3) Chemotherapy Excision and postoperative




54 Perineum, (10) Surgery None No evidence of disease Iannicelli, 2008 [8]
48 Labium majus,
(5 × 4.5 × 2.5)
Excision and lymph node
dissection
None No evidence of disease Adegboyega, 2011 [9]
54 Vaginal vestible, (3 × 2) Excision and lymph node
dissection, postoperative
concurrent chemoradiotherapy
Chemotherapy for the lung
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Conclusions
In conclusion, we report a patient with EPC of the
vulva and summarize the clinical features and the treat-
ment options using the few available retrospective case
reports. The diagnostic assessment of a biopsy speci-
men, which may not contain definitive histological
features, can lead to a misdiagnosis of SCC. Although
EPC is a rare disease, clinicians and pathologists should
be aware of its clinical and histological features and its
biological behavior.
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